Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA7 | P43166 | 3/20 | 0.45 |
| ▸ | CA6 | P23280 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13801171 | 0.81 | UHRF1 (0.48) | UHRF1PTGS2ROCK1 | |
| SCHEMBL3449694 | 0.79 | UHRF1 (0.46) | UHRF1MAPT | |
| SCHEMBL30410070 | 0.79 | UHRF1 (0.46) | UHRF1MAPT | |
| SCHEMBL3466579 | 0.79 | UHRF1 (0.46) | CA1CA2UHRF1CA12CA7 | |
| SCHEMBL26308907 | 0.78 | UHRF1 (0.45) | UHRF1MAPT | |
| SCHEMBL25463208 | 0.76 | LMNA (0.50) | CA1CA2UHRF1CA9CA12 | |
| SCHEMBL22601565 | 0.76 | CA1 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL21187203 | 0.76 | UHRF1 (0.52) | UHRF1LRRK2 | |
| SCHEMBL24669127 | 0.75 | CA2 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL23364654 | 0.75 | CA1 (0.47) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-2707102-B1 | CARBONIC ANHYDRASE TARGETING AGENTS AND METHODS OF USING SAME | VISEN MEDICAL INC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-9564274-B2 | Metal complex dye, photoelectric conversion element, dye-sensitized solar cell, dye solution, and compound | FUJIFILM CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9315494-B2 | Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140290746-A1 | METAL COMPLEX DYE, PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, DYE SOLUTION, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | VISEN MEDICAL, INC. | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | CA1 4057/4885CA2 597/4885UHRF1 4339/4885 |
| US-20120321563-A1 | Carbonic Anhydrase Targeting Agents and Methods of Using Same | CA4, CA12, CA9 | CA1 7/4885CA2 4/4885UHRF1 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.